Circulation Reports
Online ISSN : 2434-0790
Corrigendum
CORRIGENDUM: Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model
Sho ToriiTadashi YamamotoNorihito NakamuraTakeshi IjichiAyako YoshikawaYusuke ItoAtsuhiro SugidachiYuji IkariGaku Nakazawa
著者情報
ジャーナル オープンアクセス HTML

2022 年 4 巻 1 号 p. 70-71

詳細

The authors apologize for the written mistakes in the Result sections. Corrections are shown below.

1) From Page 507, Line 21 to Page 508, Line 2

Incorrect:

The volume of the thrombus (amount of protein) around stent struts was lowest in the Triple group, followed by the Prasugrel+OAC and conventional DAPT groups, and was highest in the Control group (median [IQR] 0.49 [0.38–1.11], 0.74 [0.46–1.34], 0.96 [0.50–1.41], 2.92 [2.14–4.24], and 3.72 [2.30–5.15] mg/mL in the Triple, Prasugrel+OAC, Conventional DAPT, Aspirin+OAC, and Control groups, respectively; Figure 4; Table 1).

Correct:

The volume of the thrombus (amount of protein) around stent struts was lowest in the Triple group, followed by the Prasugrel+OAC and conventional DAPT groups, and was highest in the Control group (median [IQR] 0.49 [0.38–1.11], 0.74 [0.46–1.34], 0.96 [0.50–1.41], 2.92 [2.14–4.24], and 3.73 [2.30–5.15] mg/mL in the Triple, Prasugrel+OAC, Conventional DAPT, Aspirin+OAC, and Control groups, respectively; Figure 4; Table 1).

2) Page 508, Table 1

Table 1. Differences in the Volume of the Thrombus Around Stent Struts
Group 1 vs. Group 2 Thrombus volume:
Group 1 vs. Group 2 (mg/mL)
P value
Control vs. Triple 3.73 vs. 0.49 0.003
Control vs. Prasugrel+OAC 3.73 vs. 0.74 0.005
Control vs. DAPT 3.73 vs. 0.96 0.007
Control vs. Aspirin+OAC 3.73 vs. 2.92 0.9
Triple vs. Prasugrel+OAC 0.49 vs. 0.74 0.99
Triple vs. DAPT 0.49 vs. 0.96 0.99
Triple vs. Aspirin+OAC 0.49 vs. 2.92 0.02
Prasugrel+OAC vs. DAPT 0.74 vs. 0.96 0.99
Prasugrel+OAC vs. Aspirin+OAC 0.74 vs. 2.92 0.03
DAPT vs. Aspirin+OAC 0.96 vs. 2.92 0.04

DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; Triple, treatment with prasugrel, aspirin, and warfarin.

3) Page 508, Table 2

Table 2. Difference in Bleeding Time
Group 1 vs. Group 2 Bleeding time:
Group 1 vs. Group 2 (s)
P value
Control vs. Triple 210 vs. 900 0.08
Control vs. Prasugrel+OAC 210 vs. 345 0.99
Control vs. DAPT 210 vs. 270 0.99
Control vs. Aspirin+OAC 210 vs. 405 0.99
Triple vs. Prasugrel+OAC 900 vs. 345 0.1
Triple vs. DAPT 900 vs. 270 0.04
Triple vs. Aspirin+OAC 900 vs. 405 0.2
Prasugrel+OAC vs. DAPT 345 vs. 270 0.99
Prasugrel+OAC vs. Aspirin+OAC 345 vs. 405 0.99
DAPT vs. Aspirin+OAC 270 vs. 405 0.9

DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; Triple, treatment with prasugrel, aspirin, and warfarin.

 
© 2022, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top